Turns Out, It Wasn't Bad News for Intra-Cellular Therapies

What happened

The Food and Drug Administration told Intra-Cellular Therapies (NASDAQ: ITCI) that it doesn't plan to hold an advisory committee meeting to review Intra-Cellular's marketing application for lumateperone as a treatment of schizophrenia.

There's two ways to interpret that:

  1. The FDA thinks the meeting is a waste of time, because it's already planning on rejecting the drug and doesn't think its outside advisors will be able to change the agency's opinion.

  2. The agency doesn't have any issues with the marketing application and is planning on approving the drug, so why waste its outside advisors' time?

Investors seem to have had both opinions today, having sent shares down over 18%, only to bid them back up into the black.

A U-turn arrow painted on cement

Image source: Getty Images.

So what

The FDA had previously scheduled an advisory committee meeting for the end of July, but the agency canceled it after Intra-Cellular submitted additional nonclinical information. At the time, Intra-Cellular said the FDA canceled that meeting "to allow sufficient time to review this new and any forthcoming information."

Intra-Cellular submitted even more nonclinical results that the FDA asked for. The company thinks the data support the idea that animals and humans metabolize the drug differently, so safety issues seen in animals aren't relevant to humans. Without seeing the data, investors have to trust management's interpretation; that's generally an issue when investing in most biotech companies, and it may account for the difference in opinions today.

Now what

The FDA is scheduled to make a decision about whether to approve lumateperone on or before Dec. 27. Given the holiday week, the agency may make a decision early, giving Intra-Cellular an early Christmas present.

Let's hope it's not a lump of coal.

10 stocks we like better than Intra-Cellular Therapies
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Intra-Cellular Therapies wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks


*Stock Advisor returns as of June 1, 2019


Brian Orelli has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos

    The Motley Fool

    Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

    Learn More